Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
INSM

INSM - Insmed Inc Stock Price, Fair Value and News

23.60USD-0.56 (-2.32%)Market Closed

Market Summary

INSM
USD23.60-0.56
Market Closed
-2.32%

INSM Alerts

  • 7 major insider sales recently.
  • Losses in recent quarter

INSM Stock Price

View Fullscreen

INSM RSI Chart

INSM Valuation

Market Cap

3.6B

Price/Earnings (Trailing)

-4.81

Price/Sales (Trailing)

11.38

EV/EBITDA

-6

Price/Free Cashflow

-6.1

INSM Price/Sales (Trailing)

INSM Profitability

EBT Margin

-235.89%

Return on Equity

160.69%

Return on Assets

-64.44%

Free Cashflow Yield

-16.39%

INSM Fundamentals

INSM Revenue

Revenue (TTM)

315.5M

Rev. Growth (Yr)

15.77%

Rev. Growth (Qtr)

-9.79%

INSM Earnings

Earnings (TTM)

-746.9M

Earnings Growth (Yr)

1.67%

Earnings Growth (Qtr)

15.57%

Breaking Down INSM Revenue

52 Week Range

18.3127.59
(Low)(High)

Last 7 days

-3.0%

Last 30 days

0.3%

Last 90 days

-11.0%

Trailing 12 Months

26.2%

How does INSM drawdown profile look like?

INSM Financial Health

Current Ratio

1.8

Debt/Equity

-2.02

Debt/Cashflow

-0.61

INSM Investor Care

Shares Dilution (1Y)

8.92%

Diluted EPS (TTM)

-5.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024315.5M000
2023257.5M269.5M280.8M305.2M
2022201.4M221.2M242.2M245.4M
2021167.8M170.6M173.8M188.5M
2020151.4M163.9M168.7M164.4M
201937.2M64.5M100.6M136.5M
20183.5M6.1M8.5M17.3M
2017588.0K593.0K781.0K1.6M
2016408.0K504.0K567.0K604.0K
20154.0M2.1M178.0K261.0K
20149.6M7.7M5.8M0
20135.3M7.4M9.4M11.5M
20123.2M000
20116.6M5.7M4.3M4.4M
201009.2M8.1M6.9M
200900010.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Insmed Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 17, 2024
adsett roger
sold
-149,160
25.09
-5,945
chief operating officer
May 17, 2024
flammer martina m.d.
sold
-232,936
25.09
-9,284
chief medical officer
May 14, 2024
schaeffer orlov s nicole
sold
-166,149
25.53
-6,508
chief people strategy officer
May 14, 2024
smith michael alexander
sold
-258,724
25.4
-10,186
chief legal officer
May 14, 2024
lewis william
sold
-566,493
25.52
-22,198
chair and ceo
May 14, 2024
wise john drayton
sold
-259,183
25.47
-10,176
chief commercial officer
May 14, 2024
adsett roger
sold
-200,354
25.5
-7,857
chief operating officer

1–10 of 50

Which funds bought or sold INSM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
72.61
262,077
775,077
0.10%
May 17, 2024
Ikarian Capital, LLC
new
-
1,392,720
1,392,720
0.15%
May 16, 2024
JANE STREET GROUP, LLC
added
139
3,850,430
7,351,500
-%
May 16, 2024
COMERICA BANK
sold off
-100
-2,284
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-84.38
-777,895
135,081
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.76
-783,334
3,692,580
-%
May 16, 2024
COMERICA BANK
added
3,984
1,306,410
1,344,020
0.01%
May 15, 2024
TANG CAPITAL MANAGEMENT LLC
sold off
-100
-5,150,630
-
-%
May 15, 2024
Walleye Trading LLC
reduced
-10.34
-33,198
121,163
-%
May 15, 2024
Novo Holdings A/S
unchanged
-
-5,169,710
36,335,300
2.51%

1–10 of 29

Are Funds Buying or Selling INSM?

Are funds buying INSM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INSM
No. of Funds

Unveiling Insmed Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 16, 2024
t. rowe price investment management, inc.
4.1%
5,850,606
SC 13G/A
Feb 14, 2024
t. rowe price investment management, inc.
4.1%
5,850,606
SC 13G
Feb 14, 2024
price t rowe associates inc /md/
7.5%
10,779,225
SC 13G/A
Feb 13, 2024
vanguard group inc
9.87%
14,125,521
SC 13G/A
Jan 25, 2024
blackrock inc.
8.0%
11,492,282
SC 13G/A
Jan 22, 2024
state street corp
4.15%
5,929,933
SC 13G/A
Nov 13, 2023
vanguard group inc
10.07%
14,410,356
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
6.2%
8,374,675
SC 13G
Feb 14, 2023
price t rowe associates inc /md/
7.4%
9,977,911
SC 13G/A
Feb 14, 2023
palo alto investors lp
4.33%
5,871,291
SC 13G/A

Recent SEC filings of Insmed Inc

View All Filings
Date Filed Form Type Document
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading
May 15, 2024
4
Insider Trading

Peers (Alternatives to Insmed Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Insmed Inc News

Latest updates
Simply Wall St7 hours ago
Yahoo Finance08 May 202407:00 am
Simply Wall St06 May 202407:00 am
Yahoo Finance10 Apr 202407:00 am

Insmed Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-9.8%75,500,00083,693,00079,072,00077,229,00065,214,00059,300,00067,730,00065,221,00053,107,00056,124,00046,757,00045,366,00040,214,00041,415,00043,643,00042,495,00036,860,00045,708,00038,885,00029,972,00021,902,000
Gross Profit---------------33,021,00032,545,00028,422,00037,002,00032,448,00025,053,00017,752,000
Costs and Expenses-15.6%221,005,000261,965,000226,740,000312,757,000213,372,000210,775,000195,427,000153,537,000142,940,000155,202,000150,374,000133,932,000124,047,000135,953,00099,866,00096,609,00097,217,000108,296,00088,936,00087,219,00087,261,000
  S&GA Expenses-100.0%-89,530,00090,626,00084,431,00079,914,00073,479,00075,583,00059,974,00056,748,00065,266,00060,280,00057,177,00051,550,00056,019,00046,585,00049,663,00051,346,00050,206,00053,347,00052,433,00054,810,000
  R&D Expenses-11.6%121,083,000137,029,000109,148,000196,969,000127,865,000124,763,00099,872,00088,527,00084,356,00076,352,00070,347,00064,655,00061,390,00067,814,00041,411,00035,748,00036,184,00032,630,00034,340,00033,538,00031,203,000
EBITDA Margin3.8%-2.08-2.16-2.27-2.33-1.93-1.83-1.68-1.73-1.96-2.05-2.18-1.94---------
Interest Expenses1.2%21,042,00020,784,00020,288,00020,619,00020,003,00016,445,0003,353,0003,357,0003,291,00011,350,00011,245,00010,319,0007,559,0007,499,0007,185,0007,469,0007,411,0007,348,0006,846,0006,785,0006,726,000
Income Taxes-41.9%589,0001,013,000544,000500,000483,000118,000372,000500,000400,000-27,500-2,600,000600,000239,000634,000300,000400,00036,000327,000100,000100,000200,000
Earnings Before Taxes15.4%-156,502,000-185,063,000-158,389,000-244,279,000-159,281,000-159,998,000-130,773,000-95,144,000-94,236,000-113,019,000-115,292,000-116,699,000-91,402,000-101,592,000-63,342,000-61,426,000-66,328,000-52,664,000-60,534,000-66,424,000-73,938,000
EBT Margin3.6%-2.36-2.45-2.57-2.58-2.12-1.96-1.79-1.89-2.18-2.32-2.45-2.19---------
Net Income15.6%-157,091,000-186,061,000-158,933,000-244,809,000-159,764,000-160,123,000-131,145,000-95,645,000-94,621,000-112,978,000-112,714,000-117,321,000-91,641,000-102,213,000-63,659,000-61,854,000-66,364,000-52,988,000-60,682,000-66,514,000-74,153,000
Net Income Margin3.6%-2.37-2.46-2.58-2.58-2.12-1.96-1.79-1.88-2.17-2.31-2.44-2.20---------
Free Cashflow-41.9%-188,714,000-132,972,000-139,187,000-127,675,000-149,701,000-107,840,000-90,410,000-105,205,000-106,862,000-85,274,000-76,926,000-78,929,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-12.8%1,1591,3301,3251,4391,5181,6569951,0531,1531,2441,3121,230692796841885677742763803596
  Current Assets-18.3%7599299271,0521,1291,2736326757568379591,038501623667707493555596649455
    Cash Equivalents23.5%5964824876139691,074415416516717847928410533589642429487536601420
  Inventory-0.3%83.0083.0078.0077.0071.0070.0066.0067.0064.0067.0067.0060.0052.0050.0043.0035.0031.0028.0023.0020.0013.00
  Net PPE5.0%69.0065.0065.0062.0060.0056.0054.0054.0053.0053.0053.0054.0053.0054.0055.0057.0059.0060.0053.0039.0028.00
  Goodwill0%136136136136136136136136136136136----------
Liabilities-2.3%1,6241,6621,6141,5951,5621,5681,0251,0091,033833807699491520484480470481459446452
  Current Liabilities86.5%42122619720418819013811412513511310081.0011984.0079.0072.0085.0085.0086.0094.00
  Long Term Debt-18.7%9391,1551,1481,1401,1321,125785784783567558549362356351346341336331326321
    LT Debt, Current-224--------------------
    LT Debt, Non Current-100.0%-1,1551,1481,1401,1321,125785784783567558549362356351346341336331326321
Shareholder's Equity-40.0%-464-331---44.6588.00-44.00120410505531202276357405207262304357144
  Retained Earnings-4.6%-3,603-3,446-3,260-3,101-2,856-2,696-2,536-2,405-2,309-2,265-2,152-2,039-1,922-1,830-1,728-1,664-1,602-1,536-1,483-1,422-1,356
  Additional Paid-In Capital0.8%3,1393,1132,9712,9452,8092,7822,5072,4492,4292,6742,6562,5692,1232,1052,0842,0691,8091,7971,7871,7791,500
Shares Outstanding0.4%149148143143136136120120119112110110---------
Float----3,000---2,300---3,200---2,800---2,300-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-40.7%-184,035-130,819-136,333-122,792-146,303-103,149-89,828-102,301-105,161-84,132-75,445-75,444-128,281-66,792-58,668-35,953-57,935-44,404-52,368-80,030-73,847
  Share Based Compensation7.3%21,45019,98319,99318,35916,44314,95015,65414,25912,82311,52012,23111,73510,5358,7798,9099,4689,0025,8886,7947,3536,936
Cashflow From Investing16279.4%295,3211,8037,147-274,15641,60220,30949,418-2,904-101,407-51,218-8,401-3,485-1,181-1,515-747-1,881-2,679-13,038-14,592-10,610-4,028
Cashflow From Financing-97.5%3,022123,2631,24944,326-399743,38737,1166,3116,4595,7102,536597,5976,70312,0116,102250,7562,1349,2381,358271,6333,049
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

INSM Income Statement

2024-03-31
Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]  
Product revenues, net$ 75,500$ 65,214
Revenue from Contract with Customer, Product and Service [Extensible List]Product [Member]Product [Member]
Operating expenses:  
Cost of product revenues (excluding amortization of intangible assets)$ 17,457$ 13,830
Cost, Product and Service [Extensible List]Product [Member]Product [Member]
Research and development$ 121,083$ 127,865
Selling, general and administrative93,10279,914
Amortization of intangible assets1,2631,263
Change in fair value of deferred and contingent consideration liabilities(11,900)(9,500)
Total operating expenses221,005213,372
Operating loss(145,505)(148,158)
Investment income8,78310,524
Interest expense(21,042)(20,003)
Change in fair value of interest rate swap2,362(1,533)
Other expense, net(1,100)(111)
Loss before income taxes(156,502)(159,281)
Provision for income taxes589483
Net loss$ (157,091)$ (159,764)
Basic net loss per share (in dollars per share)$ (1.06)$ (1.17)
Diluted net loss per share (in dollars per share)$ (1.06)$ (1.17)
Weighted average basic common shares outstanding (in shares)148,456136,355
Weighted average diluted common shares outstanding (in shares)148,456136,355
Net loss$ (157,091)$ (159,764)
Other comprehensive income (loss):  
Foreign currency translation losses(855)(171)
Unrealized (loss) gain on marketable securities(36)498
Total comprehensive loss$ (157,982)$ (159,437)

INSM Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 595,729$ 482,374
Marketable securities0298,073
Accounts receivable37,16241,189
Inventory82,95783,248
Prepaid expenses and other current assets42,87424,179
Total current assets758,722929,063
Fixed assets, net68,66065,384
Finance lease right-of-use assets20,30720,985
Operating lease right-of-use assets17,15718,017
Intangibles, net62,44163,704
Goodwill136,110136,110
Other assets95,69896,574
Total assets1,159,0951,329,837
Current liabilities:  
Accounts payable and accrued liabilities189,362214,987
Current portion of long-term debt224,1940
Finance lease liabilities2,6952,610
Operating lease liabilities4,6098,032
Total current liabilities420,860225,629
Debt, long-term939,0811,155,313
Royalty financing agreement156,967155,034
Contingent consideration63,70084,600
Finance lease liabilities, long-term26,32027,026
Operating lease liabilities, long-term13,80911,013
Other long-term liabilities3,1663,145
Total liabilities1,623,9031,661,760
Shareholders’ equity:  
Common stock, $0.01 par value; 500,000,000 authorized shares, 148,560,882 and 147,977,960 issued and outstanding shares at March 31, 2024 and December 31, 2023, respectively1,4861,480
Additional paid-in capital3,138,5783,113,487
Accumulated deficit(3,603,236)(3,446,145)
Accumulated other comprehensive loss(1,636)(745)
Total shareholders’ deficit(464,808)(331,923)
Total liabilities and shareholders’ deficit$ 1,159,095$ 1,329,837
INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
 CEO
 WEBSITEinsmed.com
 INDUSTRYBiotechnology
 EMPLOYEES736

Insmed Inc Frequently Asked Questions


What is the ticker symbol for Insmed Inc? What does INSM stand for in stocks?

INSM is the stock ticker symbol of Insmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Insmed Inc (INSM)?

As of Wed May 22 2024, market cap of Insmed Inc is 3.59 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INSM stock?

You can check INSM's fair value in chart for subscribers.

What is the fair value of INSM stock?

You can check INSM's fair value in chart for subscribers. The fair value of Insmed Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Insmed Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INSM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Insmed Inc a good stock to buy?

The fair value guage provides a quick view whether INSM is over valued or under valued. Whether Insmed Inc is cheap or expensive depends on the assumptions which impact Insmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INSM.

What is Insmed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, INSM's PE ratio (Price to Earnings) is -4.81 and Price to Sales (PS) ratio is 11.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INSM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Insmed Inc's stock?

In the past 10 years, Insmed Inc has provided 0.062 (multiply by 100 for percentage) rate of return.